Stirnadel-Farrant HA, Xu X, Kwiatek J, Jain P, Meyers J, Candrilli S, Mines D, Datto CJ. Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: a retrospective analysis of US health insurance claims data. JAAD Int. 2023 Jun 9;13:117-25. doi: 10.1016/j.jdin.2023.04.014
Malcomson L, Dalal G, Vass C, Wright S, Gray E, Trenaman L, Payne K, Renehan A. Introducing PrefCoRe: quantifying and implementing patient preferences for the treatment of high-risk rectal cancer, including the new strategy of organ preservation. Poster presented at the 2020 Association of Coloproctology (ACPGBI) Virtual Conference; July 2020. [abstract] Colorectal Dis. 2020 Jul; 22(S1):41-2.
Ritter A, Mellor R, Chalmers J, Sunderland M, Lancaster K. Key considerations in planning for substance use treatment: estimating treatment need and demand. J Stud Alcohol Suppl. 2019 Jan;Supp1 18:22-30. doi: 10.15288/jsads.2019.s18.22
Hunter JE, Arnold KA, Cook JE, Zepp J, Gilmore MJ, Rope AF, Davis JV, Bergen KM, Esterberg E, Muessig KR, Peterson SK, Syngal S, Acheson L, Wiesner G, Reiss J, Goddard KAB. Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Fam Cancer. 2017 Jul;16(3):377-87. doi: 10.1007/s10689-017-9972-2
Huang K, Gutierrez LP, Bulow S, Gallinger S, Castells A, Eagle CJ, Church JM. Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study. Fam Cancer. 2011 Jun 1;10(2):303-8.
Mangel AW, Williams VSL. Asimadoline in the treatment of irritable bowel syndrome. Expert Opin Investig Drugs. 2010 Oct 1;19(10):1257-64.